LOS ANGELES, March 12, 2021 (GLOBE NEWSWIRE) — via InvestorWire — InvestorBrandNetwork (“IBN”), a multifaceted communications organization engaged in connecting public companies to the investment community, is pleased to announce the release of the latest episode of The Bell2Bell Podcast as part of its sustained effort to provide specialized content distribution via widespread syndication channels.
The Bell2Bell Podcast delivers informative updates and exclusive interviews with executives operating in fast-moving industries. Bell2Bell’s latest podcast features Hugh Rogers, CEO and Director of XPhyto Therapeutics Corp. (CSE: XPHY) (OTCQB: XPHYF) (FSE: 4XT).
As discussed in the podcast, XPhyto Therapeutics recently received ISO certification for its rapid point-of-care COVID-19 PCR diagnostic test.
“We expect to be in the market very soon, within 30 days, pending European approval right now,” Rogers said. “Testing is highly relevant and will be for many years to come. The virus is endemic. It appears that it will be a forever problem. It will be active at all times for the foreseeable future somewhere in the world, and testing is a major part of managing that situation. The rollout of vaccines will not be uniform across the globe. There will be significant discrepancies, primarily for logistical and economic reasons, between the developing world and the developed world. Any time there’s international travel, and in particular between jurisdictions with disparity of economic comfort or success, there’s going to be this need for ongoing testing.”
Rogers then explained how the company’s COVID-19 test differs from diagnostics currently in use around the world.
“There are three different tests out there. The PCR is the diagnostic standard. If a doctor diagnoses you with COVID-19, it’s via a PCR test. Antigen tests tend to be cheaper and disposable but significantly less accurate. Serology tests are looking at your immune reaction and are really only relevant in terms of whether you have been exposed in the past,” he said.
“When we set out to develop a powerful tool, what we wanted was the accuracy of a PCR test with the speed of an antigen test. We focused on a highly portable, rapid PCR test. It requires significantly less training and less equipment than a standard PCR and can, therefore, be operated at a mobile or satellite laboratory, so it’s combining certain aspects of these antigen tests but delivering the accuracy and accepted standard of a PCR test.”
To hear the episode in its entirety and subscribe for future episodes, visit: https://podcast.bell2bell.com
Rogers then discussed potential markets and why a PCR test that delivers rapid onsite results can provide significant advantages over tests that must be performed in a centralized lab.
“We believe it’s the fastest PCR kit in the world. We’ve designed this system to be point-of-care, with test results ready onsite in less than 30 minutes. Any type of international travel, whether at an airport, a cruise ship terminal or simply border control if you’re traveling by car, is a potential market. Another is the transportation industry, or any time people are moving around, like migrant worker situations. We see a lot of opportunities, and we’re focusing more on the satellite lab market. It’s a slightly different opportunity, but it’s an enormous market certainly.”
Join InvestorBrandNetwork’s Jonathan Keim and Hugh Rogers, CEO and Director of XPhyto Therapeutics Corp. (CSE: XPHY) (OTCQB: XPHYF) (FSE: 4XT), to learn more about XPhyto Therapeutics’ rapid COVID-19 PCR test, as well as the company’s other product lines, including diagnostics, drug formulation and its emerging pharmaceutical psychedelics business.
To hear the whole episode and subscribe for future episodes, visit https://podcast.bell2bell.com.
The latest installment of The Bell2Bell Podcast continues to reinforce InvestorBrandNetwork’s commitment to the expansion of its robust network of brands, client partners, followers and the growing IBN Podcast Series. For more than 15 years, IBN has leveraged this commitment to provide unparalleled distribution and corporate messaging solutions to 500+ public and private companies.
To learn more about IBN’s achievements and milestones via a visual timeline, visit: https://IBN.fm/TimeLine
The InvestorBrandNetwork (“IBN”) consists of financial brands introduced to the investment public over the course of 15+ years. With IBN, we have amassed a collective audience of millions of social media followers. These distinctive investor brands aim to fulfill the unique needs of a growing base of client-partners. IBN will continue to expand our branded network of highly influential properties, leveraging the knowledge and energy of specialized teams of experts to serve our increasingly diversified list of clients.
Through NetworkNewsWire (“NNW”) and its affiliate brands, IBN provides: (1) access to a network of wire solutions via InvestorWire to reach all target markets, industries and demographics in the most effective manner possible; (2) article and editorial syndication to 5,000+ news outlets; (3) enhanced press release solutions to ensure maximum impact; (4) full-scale distribution to a growing social media audience; (5) a full array of corporate communications solutions; and (6) a total news coverage solution.
For more information on IBN, visit https://www.InvestorBrandNetwork.com.
This release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. All forward-looking statements are inherently uncertain as they are based on current expectations and assumptions concerning future events or future performance of the company. Readers are cautioned not to place undue reliance on these forward-looking statements, which are only predictions and speak only as of the date hereof. In evaluating such statements, prospective investors should review carefully various risks and uncertainties identified in this release and matters set in the company’s SEC filings. These risks and uncertainties could cause the company’s actual results to differ materially from those indicated in the forward-looking statements.